Outperform Rating Reaffirmed for Immuneering's Stock Amidst Promising IMM-1-104 Phase 2a Study Results
Immuneering Price Target Maintained With a $15.00/Share by Needham
Immuneering Analyst Ratings
Chardan Raises Price Target on Immuneering to $13 From $12, Maintains Buy Rating
Morgan Stanley Maintains Immuneering(IMRX.US) With Hold Rating, Maintains Target Price $4
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), McKesson (MCK) and Neurocrine (NBIX)
Positive Phase 2a Trial Data Reinforces Buy Rating for Immuneering's Stock
Immuneering Analyst Ratings
Buy Rating on Immuneering: Fast-Track FDA Designation and Promising Clinical Trials Underpin Positive Outlook
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Eli Lilly & Co (LLY) and Teva Pharmaceutical (TEVA)
Buy Rating Affirmed for Immuneering With $8 Price Target Amidst Promising Pipeline and Upcoming Data Events
Oppenheimer Keeps Their Buy Rating on Immuneering (IMRX)
Immuneering Analyst Ratings
Buy Rating Maintained for Immuneering Amid Promising Clinical Pipeline Developments
Buy Rating Affirmed: Immuneering's Lead Asset IMM-1-104 Shows Promise Despite Market Skepticism
Analysts' Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)
Immuneering Analyst Ratings
Immuneering Analyst Ratings
Buy Rating Affirmed for Immuneering on Solid Trial Progress and Insider Confidence
Analysts Are Bullish on These Healthcare Stocks: Immuneering (IMRX), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
No Data
No Data